ClinicalTrials.gg

Program

deucravacitinib

Also written as “BMS-986165”, “Deucravacitinib” and “BMS-986165 Tablet”.

Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Arthritis, Psoriatic · Crohn Disease · Colitis, Ulcerative, led by 2 companies.

Furthest: phase 4, since Jul 27, 202260 company-led studies, 12 open or runningNext primary completion: Nov 18, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb5912 open or runningphase 4since Jul 27, 2022Oct 3, 2016Nov 18, 2026phase 3 · NCT05946941
AbbVie10 open or runningphase 4since Mar 21, 2024Mar 21, 2024none ahead

Also a collaborator on its studies: covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Oct 3, 2016.

  1. Sep 23, 2022Phase 2 study in Alopecia AreataBristol-Myers Squibb · NCT05556265 · 94 enrolled · United States, Australia, Canada and more
  2. Nov 8, 20222 phase 3 studies in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT05617677, NCT05620407
  3. Jan 16, 2023Phase 4 study in PsoriasisBristol-Myers Squibb · NCT05701995 · 180 enrolled · United States, Puerto Rico
  4. Jul 7, 2023Phase 3 study in Sjogren's SyndromeBristol-Myers Squibb · NCT05946941 · 774 enrolled · United States, Argentina, Australia and more
  5. Sep 12, 2023Phase 4 study in Palmoplantar PsoriasisBristol-Myers Squibb · NCT06042920 · 130 enrolled · United States, Argentina, Canada
  6. Mar 21, 2024AbbVie's first study: phase 4 study in Moderate Plaque PsoriasisNew to AbbVieAbbVie · NCT06333860 · 393 enrolled · United States, Australia, Belgium and more
  7. Jun 21, 2024Phase 4 study in Healthy VolunteersBristol-Myers Squibb · NCT06476834 · 8 enrolled · United States
  8. Aug 21, 2024Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT06566768 · 52 enrolled · United Kingdom
  9. Jan 22, 2025Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT06851871 · 26 enrolled · United States
  10. Mar 6, 2025Phase 3 study in Arthritis, JuvenileBristol-Myers Squibb · NCT06869551 · 60 planned · United States, Brazil, Bulgaria and more
  11. Mar 12, 2025Phase 4 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT06875960 · 35 planned · United States
  12. May 13, 2025Phase 3 study in PsoriasisBristol-Myers Squibb · NCT06979453 · 366 planned · United States, Argentina, Belgium and more
  13. Aug 4, 2025Phase 3 study in Plaque PsoriasisBristol-Myers Squibb · NCT07116967 · 3,040 planned · United States, Argentina, Australia and more
  14. Aug 25, 2026Phase 3 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT07791199 · 2,300 planned

Ahead

  1. Nov 18, 2026Primary completion: phase 3 study in Sjogren's SyndromeBristol-Myers Squibb · NCT05946941
  2. Jan 31, 2028Primary completion: phase 4 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT06875960
  3. Jan 1, 2029Primary completion: phase 3 study in PsoriasisBristol-Myers Squibb · NCT04772079
  4. Oct 12, 2029Primary completion: phase 3 study in PsoriasisBristol-Myers Squibb · NCT06979453

TargetBeta

TYK2 →read by rule
“Tyrosine-protein kinase TYK2 negative allosteric modulator”ChEMBL 37, by rule

Other programs on TYK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
D-2570ruleInventisBiophase 313
HS-10374Hansoh Pharmaceutical Groupphase 36
TQH3906Sino Biopharmaceuticalphase 36
FXS5626Fosun Pharmaphase 33
TYK2 Inhibitorruleusynova-pharmaceuticals-ltdno phase1

Studies

All 60 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07791199Lupus Erythematosus, Systemic3Not yet recruitingBristol-Myers SquibbOct 31, 20302,300
NCT07116967Plaque Psoriasis · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbJan 16, 20313,040
NCT06979453Psoriasis · United States, Argentina, Belgium and more3RecruitingBristol-Myers SquibbOct 12, 2029366
NCT06875960Lupus Erythematosus, Systemic · United States4RecruitingBristol-Myers SquibbJan 31, 202835
NCT06869551Arthritis, Juvenile · United States, Brazil, Bulgaria and more3RecruitingBristol-Myers SquibbMar 6, 203060
NCT06851871Healthy Participants · United States1CompletedBristol-Myers SquibbApr 4, 202526
NCT06566768Healthy Participants · United Kingdom1CompletedBristol-Myers SquibbJun 13, 202552
NCT06476834Healthy Volunteers · United States4CompletedBristol-Myers SquibbNov 2, 20248
NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more4CompletedAbbVieMar 19, 2026393
NCT06042920Palmoplantar Psoriasis · United States, Argentina, Canada4TerminatedBristol-Myers SquibbApr 25, 2025130
NCT05946941Sjogren's Syndrome · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbNov 18, 2026774
NCT05701995Psoriasis · United States, Puerto Rico4CompletedBristol-Myers SquibbAug 23, 2024180
NCT05620407Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbOct 19, 2026513
NCT05617677Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3Active, not recruitingBristol-Myers SquibbOct 19, 2026516
NCT05556265Alopecia Areata · United States, Australia, Canada and more2TerminatedBristol-Myers SquibbJan 6, 202494
NCT05478499Psoriasis · United States, France, Germany and more4CompletedBristol-Myers SquibbJan 11, 2024154
NCT04949269Healthy Participants · United States1CompletedBristol-Myers SquibbJan 3, 202261
NCT04908202Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbOct 10, 2024670
NCT04908189Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbNov 7, 2024729
NCT04877990Crohn Disease · United States, Australia, Canada and more2CompletedBristol-Myers SquibbAug 29, 202367
NCT04857034Lupus Erythematosus, Discoid · United States, Argentina, Australia and more2Active, not recruitingBristol-Myers SquibbAug 22, 202474
NCT04772079Psoriasis · Argentina, Australia, Brazil and more3RecruitingBristol-Myers SquibbJan 1, 2029153
NCT04671953Healthy Participants · United States1CompletedBristol-Myers SquibbMar 3, 202136
NCT04613518Colitis, Ulcerative · United States, Australia, Canada and more2CompletedBristol-Myers SquibbMay 31, 202338
NCT04536961Healthy Volunteers · United Kingdom1CompletedBristol-Myers SquibbDec 25, 202056
NCT04305899Healthy Participants · United States1CompletedBristol-Myers SquibbNov 25, 202040
NCT04249284Healthy Participants · United States1CompletedBristol-Myers SquibbMar 15, 202018
NCT04209699Healthy Participants · United States1CompletedBristol-Myers SquibbFeb 4, 202018
NCT04167462Psoriasis · China, Korea, Republic of, Taiwan3CompletedBristol-Myers SquibbMar 8, 2021220
NCT04113668Healthy Participants · United States1CompletedBristol-Myers SquibbNov 19, 201948
NCT04086719Healthy Male Volunteers · United States1CompletedBristol-Myers SquibbOct 29, 201916
NCT04065932Lupus · United Kingdom1CompletedBristol-Myers SquibbDec 8, 201933
NCT04055506Healthy Participants · United States1CompletedBristol-Myers SquibbSep 21, 201916
NCT04036435Psoriasis · United States, Australia, Canada and more3CompletedBristol-Myers SquibbJul 21, 20261,466
NCT03979248Healthy · Netherlands1CompletedBristol-Myers SquibbJul 7, 201921
NCT03956953Autoimmune Diseases · China1CompletedBristol-Myers SquibbSep 25, 2019135
NCT03934216Colitis, Ulcerative · United States, Australia, Belgium and more2CompletedBristol-Myers SquibbJun 13, 2021131
NCT03943147Lupus Nephritis · United States, Australia, Belgium and more2TerminatedBristol-Myers SquibbOct 29, 202016
NCT03930602Healthy · United States1CompletedBristol-Myers SquibbMay 27, 201916
NCT03924427Psoriasis · Japan3CompletedBristol-Myers SquibbMar 24, 202174
NCT03920267Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2CompletedBristol-Myers SquibbMar 21, 2025261
NCT03890809Liver Diseases · Czechia, Hungary, Slovakia1CompletedBristol-Myers SquibbNov 30, 201932
NCT03890770Renal Insufficiency · United States, Czechia, Hungary and more1CompletedBristol-Myers SquibbFeb 7, 202044
NCT03881059Active Psoriatic Arthritis · United States, Czechia, Germany and more2CompletedBristol-Myers SquibbApr 27, 2020203
NCT03873415Psoriasis · United States1CompletedBristol-Myers SquibbMay 1, 20199
NCT03739788Healthy Participants · United Kingdom1CompletedBristol-Myers SquibbFeb 11, 20198
NCT03751228Healthy Participants · United States1CompletedBristol-Myers SquibbNov 26, 20189
NCT03660436Healthy Participants · United States1CompletedBristol-Myers SquibbOct 10, 2018131
NCT03624127Psoriasis · United States, Canada, China and more3CompletedBristol-Myers SquibbSep 2, 2020666
NCT03611751Psoriasis · United States, Australia, Canada and more3CompletedBristol-Myers SquibbNov 29, 20201,020
NCT03599622Crohn Disease · United States, Australia, Belgium and more2TerminatedBristol-Myers SquibbDec 12, 2022239
NCT03541564Lupus Erythematosus, Systemic · United States1CompletedBristol-Myers SquibbSep 4, 201884
NCT03419910Psoriasis · United States1CompletedBristol-Myers SquibbMay 4, 201854
NCT03402087Arthritis, Psoriatic · Netherlands1CompletedBristol-Myers SquibbMar 20, 201830
NCT03262727Lupus Erythematosus, Systemic · United States1CompletedBristol-Myers SquibbNov 23, 201749
NCT03254784Lupus Erythematosus, Systemic · United States1CompletedBristol-Myers SquibbNov 4, 201749
NCT03252587Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedBristol-Myers SquibbJun 29, 2021363
NCT03044873Autoimmune Diseases · United States1CompletedBristol-Myers SquibbMar 14, 201720
NCT03004768Psoriasis · United States1CompletedBristol-Myers SquibbFeb 27, 20176
NCT02931838Psoriasis · United States, Australia, Canada and more2CompletedBristol-Myers SquibbNov 16, 2017268

How it is read

Names in the registry

  • “BMS-986165”, 34 entries
  • “Deucravacitinib”, 21 entries
  • “BMS-986165 Tablet”, 2 entries
  • “BMS-986165 Dose A”, 1 entry
  • “BMS-986165 Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.